Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sarah Elsayed

Cardiovascular Disease Fountain Valley, CA Medical Doctor

NPI 1396049029 CMS profile 716555

18111 Brookhurst St Ste 5100, Fountain Valley, CA 92708

Open in the dashboard

General payments

$12,072

451 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$109,258 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Sarah Elsayed of Fountain Valley, CA is reported in the CMS Open Payments database as having received $12,072 across 451 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $109,258 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,992 91
2024 General $1,901 68
2023 General $2,207 63
2022 General $1,405 67
2021 General $1,585 56
2020 General $894 50
2019 General $2,088 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sarah Elsayed
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Sarah Elsayed were reported at $1,992. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Sarah Elsayed Cardiovascular Disease median Middle half National median
2019 $2,088 $450 $127–$1,392 $163
2020 $894 $242 $77–$751 $114
2021 $1,585 $335 $101–$1,037 $132
2022 $1,405 $395 $121–$1,211 $149
2023 $2,207 $443 $136–$1,283 $160
2024 $1,901 $450 $136–$1,323 $164
2025 $1,992 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,901 61 payments
  2. Pfizer Inc. $1,143 81 payments
  3. Novartis Pharmaceuticals Corporation $1,028 57 payments
  4. Penumbra, Inc. $1,002 3 payments
  5. Inari Medical, Inc. $963 12 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $685 37 payments
  7. E.R. Squibb & Sons, L.L.C. $502 25 payments
  8. Abbott Laboratories $448 13 payments
  9. Janssen Pharmaceuticals, Inc $441 28 payments
  10. Medtronic, Inc. $439 14 payments
  11. Other $3,519 120 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,682 449 payments
  2. Travel and Lodging $383 1 payment
  3. Education $8 1 payment
Products named General payments · program years 2019–2025
  1. LifeVest $1,901 61 payments
  2. Indigo $1,002 3 payments
  3. ELIQUIS $965 73 payments
  4. CT THROMBECTOMY SYSTEM KIT $963 12 payments
  5. FLOWTRIEVER CATHETER, S $963 12 payments
  6. XARELTO $552 29 payments
  7. JARDIANCE $507 28 payments
  8. VYNDAQEL $500 47 payments
  9. LEQVIO $463 25 payments
  10. ENTRESTO $377 22 payments
  11. Other $6,652 219 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

2,384

Median for Cardiology: 2,533

Drug cost

$459,527

Median for Cardiology: $485,213

Branded share of claims

21.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 276 $315,277
Entresto Sacubitril/Valsartan Brand 27 $37,720
Xarelto Rivaroxaban Brand 26 $30,731
Multaq Dronedarone Hcl Brand 12 $17,739
Brilinta Ticagrelor Brand 21 $13,867
Repatha Sureclick Evolocumab Brand 21 $13,357
Droxidopa Generic 12 $4,504
Midodrine Hcl Generic 18 $2,912
Metoprolol Succinate Generic 211 $2,852
Rosuvastatin Calcium Generic 105 $2,518

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$161,569

Of which drugs: $483

Medicare patients

597

Average age 77

Services billed

1,999

345 women, 252 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 46%
Atrial fibrillation 43%
Diabetes 41%
Heart failure 40%
Chronic kidney disease 40%
Depression 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 20 80 $483

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $281
$281 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $168
$168 — —
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $101
$101 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $46
$46 27 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $30
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

451 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record